Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.…
New National Survey Found Many People With Sleep Apnea Struggle to Stay on Treatment
Apnimed (NASDAQ: APMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 112 employees.
The shares were at 16.09 USD on 20 November 2026. Its 52-week range is 13.88 USD to 35.29 USD: the price is 54.4% below the high and 15.9% above the low.
At a market capitalisation of 669.84M USD, it trades at 1.2 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 96% for APMD.
Apnimed reports return on equity of 0.3%, an operating margin of 11.4% and revenue down 71.8% year over year.
It holds more cash than debt, a net cash position of 301.78M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 50.00 USD is 210.8% above the current price. The next earnings report is expected on 3 March 2027.